NPPA and heart failure: Also, pharmacological aldosterone antagonism had no effect on cardiomyocyte hypertrophy (23.9 ± 0.6 vs. 20.9 ± 0.8 μm, p > 0.05) (CM diameter, Fig. 3d) and heart failure marker gene expression (221 ± 6 vs. 220 ± 16%, p > 0.05 for ANP, Fig. 3e and 167 ± 10 vs. 154 ± 4%, p > 0.05 for BNP, Fig. 3f).